Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.
Journal: Lancet (London, England)
Published: December 21, 2023
Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report.
Journal: Melanoma research
Published: June 16, 2023
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial.
Journal: Nature medicine
Published: December 09, 2021
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.
Journal: Frontiers in oncology
Published: November 19, 2021
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer.
Journal: Journal for immunotherapy of cancer
Published: October 27, 2021
Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab.
Journal: Journal for immunotherapy of cancer
Published: May 28, 2021
Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.
Journal: Hepatology (Baltimore, Md.)
Published: June 07, 2018
Fludarabine and neurotoxicity in engineered T-cell therapy.
Journal: Gene therapy
Published: October 20, 2017
Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 17, 2014
Showing 1-11 of 11
Last Updated: 09/26/2026